Cited by 1,063Receptor Mechanisms and SignalingNeuroscience and Neuropharmacology ResearchNeurotransmitter Receptor Influence on Behavior

The DOI matches its Crossref record; 139 of the 139 references it cites were found in a registry or an index.

Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders

Open access

Jeffrey Conn, P., Christopoulos, Arthur, Lindsley, Craig W.·2009·Nature Reviews Drug Discovery

DOI 10.1038/nrd2760PMC PMC2907734

Open this paper in CoChat — free account

Abstract

Despite G-protein-coupled receptors (GPCRs) being among the most fruitful targets for marketed drugs, intense discovery efforts for several GPCR subtypes have failed to deliver selective drug candidates. Historically, drug discovery programmes for GPCR ligands have been dominated by efforts to develop agonists and antagonists that act at orthosteric sites for endogenous ligands. However, in recent years, there have been tremendous advances in the discovery of novel ligands for GPCRs that act at allosteric sites to regulate receptor function. These compounds provide high selectivity, novel modes of efficacy and may lead to novel therapeutic agents for the treatment of multiple psychiatric and neurological human disorders.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nrd2760

Cites

139 of 139 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
PHARMACOLOGY AND FUNCTIONS OF METABOTROPIC GLUTAMATE RECEPTORS
Conn, P. J., & Pin, J. (1997) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.37.1.205 · Cited by 3,083
The Ecology of Freshwater Phytoplankton.
Jones, R. I., & REYNOLDS, C. S. (1985) · Journal of Ecology · doi:10.2307/2260522 · Cited by 2,817
The mGluR theory of fragile X mental retardation
Bear, M. F., Huber, K. M., & Warren, S. T. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.04.009 · Cited by 1,580
G Protein-coupled Receptors
Ji, T. H., Grossmann, M., & Ji, I. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.28.17299 · Cited by 1,281
Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity
Dorr, P. K., Westby, M., Dobbs, S., Griffin, P., Irvine, B., Macartney, M. J., Mori, J., Rickett, G., Smith‐Burchnell, C., Napier, C. M., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.11.4721-4732.2005 · Cited by 1,154
Functional Selectivity and Classical Concepts of Quantitative Pharmacology
Urban, J. D., Clarke, W. P., von Zastrow, M., Nichols, D. E., Kobilka, B. K., Weinstein, H., Javitch, J. A., Roth, B. L., Christopoulos, A., Sexton, P. M., et al. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.104463 · Cited by 1,131
Self-citation
Operational models of pharmacological agonism
Black, J. W., & Leff, P. (1983) · Proceedings of the Royal Society B Biological Sciences · doi:10.1098/rspb.1983.0093 · Cited by 1,106
Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial
Patil, S. T., Zhang, L., Martenyi, F., Lowe, S. L., Jackson, K. A., Andreev, B. V., Avedisova, A. S., Bardenstein, L. M., Gurovich, I. Y., Morozova, M. A., et al. (2007) · Nature Medicine · doi:10.1038/nm1632 · Cited by 1,040
Reversal of Phencyclidine Effects by a Group II Metabotropic Glutamate Receptor Agonist in Rats
Moghaddam, B., & Adams, B. W. (1998) · Science · doi:10.1126/science.281.5381.1349 · Cited by 1,006
G Protein-Coupled Receptor Allosterism and Complexing
Christopoulos, A., & Kenakin, T. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.323 · Cited by 934
Self-citation
2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist
Gasparini, F., Lingenhöhl, K., Stoehr, N., Flor, P. J., Heinrich, M., Vranesic, I., Biollaz, M., Allgeier, H., Heckendorn, R., Urwyler, S., et al. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(99)00082-9 · Cited by 725
A new benzodiazepine pharmacology
Möhler, H., Fritschy, J. M., & Rudolph, U. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.1.2 · Cited by 716
Allosteric Modulation of G Protein–Coupled Receptors
May, L. T., Leach, K., Sexton, P. M., & Christopoulos, A. (2006) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105159 · Cited by 698
Self-citation
Distribution of metabotropic glutamate receptor mGluR5 immunoreactivity in rat brain
Romano, C., Sesma, M. A., McDonald, C. T., O’Malley, K. L., van den Pol, A. N., & Olney, J. W. (1995) · The Journal of Comparative Neurology · doi:10.1002/cne.903550310 · Cited by 671
Allosteric binding sites on cell-surface receptors: novel targets for drug discovery
Christopoulos, A. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd746 · Cited by 665
Self-citation
Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development
Wess, J., Eglen, R. M., & Gautam, D. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2379 · Cited by 637
Metabotropic glutamate receptors as novel targets for anxiety and stress disorders
Swanson, C. J., Bures, M., Johnson, M. P., Linden, A.-M., Monn, J. A., & Schoepp, D. D. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1630 · Cited by 607
G-Protein-coupled receptor oligomerization and its potential for drug discovery
George, S. R., O’Dowd, B. F., & Lee, S. P. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd913 · Cited by 590
G Protein-coupled Receptors
Gether, U., & Kobilka, B. K. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.29.17979 · Cited by 580
Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia
Shekhar, A., Potter, W. Z., Lightfoot, J., Lienemann, J., Dubé, S., Mallinckrodt, C. H., Bymaster, F. P., McKinzie, D. L., & Felder, C. C. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.06091591 · Cited by 563
Metabotropic Glutamate Receptors 1 and 5 Differentially Regulate CA1 Pyramidal Cell Function
Mannaioni, G., Marino, M. J., Valenti, O., Traynelis, S. F., & Conn, P. J. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-16-05925.2001 · Cited by 441
A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5
Dragic, T., Trkola, A., Thompson, D. A. D., Cormier, E. G., Kajumo, F., Maxwell, E., Lin, S. W., Ying, W., Smith, S. O., Sakmar, T. P., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.090576697 · Cited by 440
Effects of ketamine and n-methyl-d-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268
Lorrain, D. S., Baccei, C. S., Bristow, L. J., Anderson, J. J., & Varney, M. A. (2003) · Neuroscience · doi:10.1016/s0306-4522(02)00652-8 · Cited by 432
3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]- pyridine: A Potent and Highly Selective Metabotropic Glutamate Subtype 5 Receptor Antagonist with Anxiolytic Activity
Cosford, N. D. P., Tehrani, L. R., Roppe, J. R., Schweiger, E. J., Smith, N. D., Anderson, J., Bristow, L. J., Brodkin, J. D., Jiang, X., McDonald, I. A., et al. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm025570j · Cited by 397
Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology
Leach, K., Sexton, P. M., & Christopoulos, A. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.06.004 · Cited by 366
Self-citation
Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods.
Ehlert, F. J. (1988) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13145-3 · Cited by 356
Metabotropic glutamate receptors in the basal ganglia motor circuit
Conn, P. J., Battaglia, G., Marino, M. J., & Nicoletti, F. (2005) · Nature reviews. Neuroscience · doi:10.1038/nrn1763 · Cited by 344
New Concepts in Drug Discovery: Collateral Efficacy and Permissive Antagonism
Kenakin, T. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1875 · Cited by 319
Fenobam: A Clinically Validated Nonbenzodiazepine Anxiolytic Is a Potent, Selective, and Noncompetitive mGlu5 Receptor Antagonist with Inverse Agonist Activity
Porter, R. H. P., Jaeschke, G., Spooren, W., Ballard, T. M., Büttelmann, B., Kolczewski, S., Peters, J.-U., Prinssen, E., Wichmann, J., Vieira, E., et al. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.089839 · Cited by 308
A Novel Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Has in Vivo Activity and Antipsychotic-Like Effects in Rat Behavioral Models
Kinney, G. G., O’Brien, J. A., Lemaire, W., Burno, M., Bickel, D. J., Clements, M. K., Chen, T., Wisnoski, D. D., Lindsley, C. W., Tiller, P. R., et al. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.079244 · Cited by 298
Self-citation
N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl- d -aspartate receptor activity
Sur, C., Mallorga, P. J., Wittmann, M., Jacobson, M. A., Pascarella, D. M., Williams, J. B., Brandish, P. E., Pettibone, D. J., Scolnick, E. M., & Conn, P. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1835612100 · Cited by 295
Physiological Antagonism between 5-Hydroxytryptamine2A and Group II Metabotropic Glutamate Receptors in Prefrontal Cortex
Marek, G. J., Wright, R. A., Schoepp, D. D., Monn, J. A., & Aghajanian, G. K. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35262-0 · Cited by 280
Orphan G-protein-coupled receptors and natural ligand discovery
Howard, A. D., McAllister, G., Feighner, S. D., Liu, Q., Nargund, R. P., der Ploeg, L. H. T. V., & Patchett, A. A. (2001) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01636-9 · Cited by 274
The Non-competitive Antagonists 2-Methyl-6-(phenylethynyl)pyridine and 7-Hydroxyiminocyclopropan[b]chromen-1a-carboxylic Acid Ethyl Ester Interact with Overlapping Binding Pockets in the Transmembrane Region of Group I Metabotropic Glutamate Receptors
Pagano, A., Rüegg, D., Litschig, S., Stoehr, N., Stierlin, C., Heinrich, M., Floersheim, P., Prézeau, L., Carroll, F. Y., Pin, J., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m006230200 · Cited by 271
Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G protein-coupled receptors: interactions of strychnine and acetylcholine at muscarinic receptors.
Lazareno, S., & Birdsall, N. J. M. (1995) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10255-1 · Cited by 266
Molecular Interactions of Cyclam and Bicyclam Non-peptide Antagonists with the CXCR4 Chemokine Receptor
Gerlach, L. O., Skerlj, R. T., Bridger, G. J., & Schwartz, T. W. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010429200 · Cited by 261
Novel Selective Allosteric Activator of the M1Muscarinic Acetylcholine Receptor Regulates Amyloid Processing and Produces Antipsychotic-Like Activity in Rats
Jones, C. K., Brady, A. E., Davis, A. A., Xiang, Z., Bubser, M., Tantawy, M. N., Kane, A. S., Bridges, T. M., Kennedy, J. P., Bradley, S. R., et al. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.1850-08.2008 · Cited by 248
Self-citation
Positive allosteric modulators of metabotropic glutamate 1 receptor: Characterization, mechanism of action, and binding site
Knoflach, F., Mutel, V., Jolidon, S., Kew, J. N. C., Malherbe, P., Vieira, E., Wichmann, J., & Kemp, J. A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.231358298 · Cited by 241
Allosteric modulation of group III metabotropic glutamate receptor 4: A potential approach to Parkinson's disease treatment
Marino, M. J., Williams, D. L., O’Brien, J. A., Valenti, O., McDonald, T. P., Clements, M. K., Wang, R., DiLella, A. G., Hess, J. F., Kinney, G. G., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1835724100 · Cited by 240
Molecular Mechanism of AMD3100 Antagonism in the CXCR4 Receptor
ROSENKILDE, M. M., Gerlach, L., Jakobsen, J. S., Skerlj, R. T., Bridger, G. J., & Schwartz, T. W. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m309546200 · Cited by 238
Allosteric modulation of the muscarinic M 4 receptor as an approach to treating schizophrenia
Chan, W. Y., McKinzie, D. L., Bose, S., Mitchell, S. N., Witkin, J. M., Thompson, R. C., Christopoulos, A., Lazareno, S., Birdsall, N. J. M., Bymaster, F. P., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0800567105 · Cited by 234
Self-citation
Spirodiketopiperazine-Based CCR5 Inhibitor Which Preserves CC-Chemokine/CCR5 Interactions and Exerts Potent Activity against R5 Human Immunodeficiency Virus Type 1 In Vitro
Maeda, K., Nakata, H., Koh, Y., Miyakawa, T., Ogata, H., Takaoka, Y., Shibayama, S., Sagawa, K., Fukushima, D., Moravek, J., et al. (2004) · Journal of Virology · doi:10.1128/jvi.78.16.8654-8662.2004 · Cited by 222
Metabotropic Glutamate Subtype 5 Receptors Modulate Locomotor Activity and Sensorimotor Gating in Rodents
Kinney, G. G., Burno, M., Campbell, U. C., Hernández, L. M., Rodriguez, D. E., Bristow, L. J., & Conn, P. J. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.048702 · Cited by 219
A Family of Highly Selective Allosteric Modulators of the Metabotropic Glutamate Receptor Subtype 5
O’Brien, J. A., Lemaire, W., Chen, T., Chang, R. S. L., Jacobson, M. A., Ha, S., Lindsley, C. W., Schaffhauser, H., Sur, C., Pettibone, D. J., et al. (2003) · Molecular Pharmacology · doi:10.1124/mol.64.3.731 · Cited by 209
Self-citation
LY354740, an mGlu2/3 Receptor Agonist as a Novel Approach to Treat Anxiety/Stress
Schoepp, D. D., Wright, R. A., Levine, L. R., Gaydos, B. L., & Potter, W. Z. (2003) · Stress · doi:10.1080/1025389031000146773 · Cited by 207
Centrally Active Allosteric Potentiators of the M4 Muscarinic Acetylcholine Receptor Reverse Amphetamine-Induced Hyperlocomotor Activity in Rats
Brady, A. E., Jones, C. K., Bridges, T. M., Kennedy, J. P., Thompson, A. D., Heiman, J. U., Breininger, M. L., Gentry, P. R., Yin, H., Jadhav, S. B., et al. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.140350 · Cited by 204
Self-citation
Evidence for the Role of Metabotropic Glutamate (mGlu)2 Not mGlu3 Receptors in the Preclinical Antipsychotic Pharmacology of the mGlu2/3 Receptor Agonist (–)-(1 R, 4 S,5 S,6 S)-4-Amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic Acid (LY404039)
Fell, M. J., Svensson, K. A., Johnson, B. G., & Schoepp, D. D. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.136861 · Cited by 204
Analysis of the Mechanism by Which the Small-Molecule CCR5 Antagonists SCH-351125 and SCH-350581 Inhibit Human Immunodeficiency Virus Type 1 Entry
Tsamis, F., Gavrilov, S., Kajumo, F., Seibert, C., Kuhmann, S. E., Ketas, T., Trkola, A., Palani, A., Clader, J. W., Tagat, J. R., et al. (2003) · Journal of Virology · doi:10.1128/jvi.77.9.5201-5208.2003 · Cited by 203
Activation of NMDA receptors reverses desensitization of mGluR5 in native and recombinant systems
Alagarsamy, S., Marino, M. J., Rouse, S. T., Gereau, R. W., Heinemann, S. F., & Conn, P. J. (1999) · Nature Neuroscience · doi:10.1038/6338 · Cited by 201
The Heptahelical Domain of GABAB2 Is Activated Directly by CGP7930, a Positive Allosteric Modulator of the GABAB Receptor
Binet, V., Brajon, C., Corre, L. L., Acher, F., Pin, J., & Prézeau, L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m400930200 · Cited by 200
(−)-PHCCC, a positive allosteric modulator of mGluR4: characterization, mechanism of action, and neuroprotection
Maj, M. (2003) · Neuropharmacology · doi:10.1016/s0028-3908(03)00271-5 · Cited by 197
Discovery of an Ectopic Activation Site on the M1Muscarinic Receptor
Spalding, T. A., Trotter, C., Skjærbæk, N., Messier, T., Currier, E. A., Burstein, E. S., Li, D., Hacksell, U., & Brann, M. R. (2002) · Molecular Pharmacology · doi:10.1124/mol.61.6.1297 · Cited by 193
Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia
Moghaddam, B. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1792-z · Cited by 189
Discovery, Characterization, and Antiparkinsonian Effect of Novel Positive Allosteric Modulators of Metabotropic Glutamate Receptor 4
Niswender, C. M., Johnson, K. A., Weaver, C. D., Jones, C. K., Xiang, Z., Luo, Q., Rodriguez, A. L., Marlo, J. E., de Paulis, T., Thompson, A. D., et al. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.049551 · Cited by 189
Self-citation
SIB-1757 and SIB-1893: Selective, Noncompetitive Antagonists of Metabotropic Glutamate Receptor Type 5
Varney, M. A., Cosford, N. D. P., Jachec, C., Rao, S. P., Sacaan, A. I., Lin, F., Bleicher, L. S., Santori, E. M., Flor, P. J., Allgeier, H., et al. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)34881-5 · Cited by 189
Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans
Grillon, C., Cordova, J., Levine, L. R., & Morgan, C. A. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1444-8 · Cited by 186
Discovery of Allosteric Potentiators for the Metabotropic Glutamate 2 Receptor: Synthesis and Subtype Selectivity of N-(4-(2-Methoxyphenoxy)phenyl)-N-(2,2,2− trifluoroethylsulfonyl)pyrid-3-ylmethylamine
Johnson, M. P., Baez, M., Jagdmann, G. E., Britton, T. C., Large, T. H., Callagaro, D. O., Tizzano, J. P., Monn, J. A., & Schoepp, D. D. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm034015u · Cited by 182
Modeling the Functional Effects of Allosteric Modulators at Pharmacological Receptors: An Extension of the Two-State Model of Receptor Activation
Hall, D. A. (2000) · Molecular Pharmacology · doi:10.1124/mol.58.6.1412 · Cited by 182
A novel class of antagonists for metabotropic glutamate receptors, 7-(Hydroxyimino)cyclopropa[b]chromen-1a-carboxylates
Annoura, H., Fukunaga, A., Uesugi, M., Tatsuoka, T., & Horikawa, Y. (1996) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/0960-894x(96)00104-7 · Cited by 180
A Selective Allosteric Potentiator of Metabotropic Glutamate (mGlu) 2 Receptors Has Effects Similar to an Orthosteric mGlu2/3 Receptor Agonist in Mouse Models Predictive of Antipsychotic Activity
Galici, R., Echemendia, N. G., Rodriguez, A. L., & Conn, P. J. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.091074 · Cited by 175
A Novel Mechanism of G Protein-coupled Receptor Functional Selectivity
Valant, C., Gregory, K. J., Hall, N. E., Scammells, P. J., Lew, M. J., Sexton, P. M., & Christopoulos, A. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m803801200 · Cited by 173
Self-citation
Positive allosteric modulation of the human metabotropic glutamate receptor 4 (hmGluR4) by SIB‐1893 and MPEP
Mathiesen, J. M., Svendsen, N., Bräuner‐Osborne, H., Thomsen, C., & Ramirez, M. T. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705159 · Cited by 173
Discovery of Positive Allosteric Modulators for the Metabotropic Glutamate Receptor Subtype 5 from a Series of N-(1,3-Diphenyl-1H- pyrazol-5-yl)benzamides That Potentiate Receptor Function in Vivo
Lindsley, C. W., Wisnoski, D. D., Leister, W., O’Brien, J. A., Lemaire, W., David L. Williams, Burno, M., Sur, C., Kinney, G. G., Pettibone, D. J., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049400d · Cited by 170
Self-citation
A Novel Selective Allosteric Modulator Potentiates the Activity of Native Metabotropic Glutamate Receptor Subtype 5 in Rat Forebrain
O’Brien, J. A., Lemaire, W., Wittmann, M., Jacobson, M. A., Ha, S., Wisnoski, D. D., Lindsley, C. W., Schaffhauser, H., Rowe, B. A., Sur, C., et al. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.061747 · Cited by 170
Self-citation
Biphenyl-indanone A, a Positive Allosteric Modulator of the Metabotropic Glutamate Receptor Subtype 2, Has Antipsychotic- and Anxiolytic-Like Effects in Mice
Galici, R., Jones, C. K., Hemstapat, R., Nong, Y., Echemendia, N. G., Williams, L. C., de Paulis, T., & Conn, P. J. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.102046 · Cited by 169
Metabotropic Glutamate Receptor Subtype 5 Antagonists MPEP and MTEP
Lea, P. M., & Faden, A. I. (2006) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2006.00149.x · Cited by 168
Functional neuroanatomy of the basal ganglia in Parkinson's disease.
Wichmann, T., & DeLong, M. R. (2003) · PubMed · Cited by 167
Group III Metabotropic Glutamate Receptor-Mediated Modulation of the Striatopallidal Synapse
Valenti, O., Marino, M. J., Wittmann, M., Lis, E. V., DiLella, A. G., Kinney, G. G., & Conn, P. J. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-18-07218.2003 · Cited by 166
Treatment of Anxiety Using Fenobam (a Nonbenzodiazepine) in a Double-Blind Standard (Diazepam) Placebo-Controlled Study
Pecknold, J. C., McClure, D., APPELTAUER, L., Wrzesinski, L., & ALLAN, T. (1982) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198204000-00010 · Cited by 165
Structural and Molecular Interactions of CCR5 Inhibitors with CCR5
Maeda, K., Das, D., Ogata-Aoki, H., Nakata, H., Miyakawa, T., Tojo, Y., Norman, R., Takaoka, Y., Ding, J., Arnold, G. F., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m512688200 · Cited by 165
Pharmacological Characterization and Identification of Amino Acids Involved in the Positive Modulation of Metabotropic Glutamate Receptor Subtype 2
Schaffhauser, H., Rowe, B. A., Morales, S., Chavez-Noriega, L. E., Yin, R., Jachec, C., Rao, S. P., Bain, G., Pinkerton, A. B., Vernier, J., et al. (2003) · Molecular Pharmacology · doi:10.1124/mol.64.4.798 · Cited by 160
An allosteric potentiator of M4 mAChR modulates hippocampal synaptic transmission
Shirey-Rice, J. K., Xiang, Z., Orton, D., Brady, A. E., Johnson, K. A., Williams, R. D., Ayala, J. E., Rodriguez, A. L., Wess, J., Weaver, D., et al. (2007) · Nature Chemical Biology · doi:10.1038/nchembio.2007.55 · Cited by 160
A Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 2 Blocks a Hallucinogenic Drug Model of Psychosis
Benneyworth, M. A., Xiang, Z., Smith, R. L., Garcia, E. E., Conn, P. J., & Sanders‐Bush, E. (2007) · Molecular Pharmacology · doi:10.1124/mol.107.035170 · Cited by 159
Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s)
Johnson, M. P., Barda, D., Britton, T. C., Emkey, R., Hornback, W. J., Jagdmann, G. E., McKinzie, D. L., Nisenbaum, E. S., Tizzano, J. P., & Schoepp, D. D. (2005) · Psychopharmacology · doi:10.1007/s00213-004-2099-9 · Cited by 156
Progress Towards Validating the NMDA Receptor Hypofunction Hypothesis of Schizophrenia
Lindsley, C. W., Shipe, W. D., Wolkenberg, S. E., Theberge, C. R., Williams, D., Jr., Sur, C., & Kinney, G. G. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/156802606777057599 · Cited by 156
Self-citation
Homology Modeling of the Transmembrane Domain of the Human Calcium Sensing Receptor and Localization of an Allosteric Binding Site
Miedlich, S. U., Gama, L., Seuwen, K., Wolf, R. M., & Breitwieser, G. E. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m307191200 · Cited by 152
Interaction of N-methyl-D-aspartate and group 5 metabotropic glutamate receptors on behavioral flexibility using a novel operant set-shift paradigm
Darrah, J. M., Stefani, M. R., & Moghaddam, B. (2008) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e3282feb0ac · Cited by 148
Activation of Group II Metabotropic Glutamate Receptors Inhibits Synaptic Excitation of the Substantia Nigra Pars Reticulata
Bradley, S. R., Marino, M. J., Wittmann, M., Rouse, S. T., Awad, H., Levey, A. I., & Conn, P. J. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-09-03085.2000 · Cited by 141
Mutations in G proteins and G protein-coupled receptors in endocrine disease.
Am, S. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.7.8675557 · Cited by 138
Probing of the location of the allosteric site on m1 muscarinic receptors by site-directed mutagenesis.
Matsui, H., Lazareno, S., & Birdsall, N. J. M. (1995) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)08527-x · Cited by 136
Mutational Analysis and Molecular Modeling of the Allosteric Binding Site of a Novel, Selective, Noncompetitive Antagonist of the Metabotropic Glutamate 1 Receptor
Malherbe, P., Kratochwil, N. A., Knoflach, F., Zenner, M., Kew, J. N. C., Kratzeisen, C., Maerki, H. P., Adam, G., & Mutel, V. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211759200 · Cited by 135
Modeling and Mutagenesis of the Binding Site of Calhex 231, a Novel Negative Allosteric Modulator of the Extracellular Ca2+-sensing Receptor
Pétrel, C., Kessler, A., Maslah, F., Dauban, P., Dodd, R. H., Rognan, D., & Ruat, M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m308010200 · Cited by 135
Direct and Indirect Modulation of the N-Methyl D-Aspartate Receptor: Potential for the Development of Novel Antipsychotic Therapies
Marino, M. J., & Conn, P. J. (2002) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1568007023339544 · Cited by 134
Substituent Effects ofN-(1,3-Diphenyl-1H-pyrazol-5-yl)benzamides on Positive Allosteric Modulation of the Metabotropic Glutamate-5 Receptor in Rat Cortical Astrocytes
de Paulis, T., Hemstapat, R., Chen, Y., Zhang, Y., Saleh, S., Alagille, D., Baldwin, R. M., Tamagnan, G. D., & Conn, P. J. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm051252j · Cited by 133
Characterization of a CNS penetrant, selective M1muscarinic receptor agonist, 77‐LH‐28‐1
Langmead, C. J., Austin, N. E., Branch, C. L., Brown, J. T., Buchanan, K. A., Davies, C. H., Forbes, I. T., Fry, V. A. H., Hagan, J. J., Herdon, H. J., et al. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.152 · Cited by 132
Muscarinic Receptors as a Target for Drugs Treating Schizophrenia
Bymaster, F. P., Felder, C. C., Ahmed, S., & McKinzie, D. L. (2002) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1568007024606249 · Cited by 131
Distinct physiological roles of the Gq‐coupled metabotropic glutamate receptors co‐expressed in the same neuronal populations
Valenti, O., Conn, P. J., & Marino, M. J. (2002) · Journal of Cellular Physiology · doi:10.1002/jcp.10081 · Cited by 125
The mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) potentiates PCP-induced cognitive deficits in rats
Campbell, U. C., Lalwani, K., Hernández, L. M., Kinney, G. G., Conn, P. J., & Bristow, L. J. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1827-5 · Cited by 123
A Close Structural Analog of 2-Methyl-6-(phenylethynyl)-pyridine Acts as a Neutral Allosteric Site Ligand on Metabotropic Glutamate Receptor Subtype 5 and Blocks the Effects of Multiple Allosteric Modulators
Rodriguez, A. L., Nong, Y., Sekaran, N. K., Alagille, D., Tamagnan, G. D., & Conn, P. J. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.016139 · Cited by 123
Pharmacological Activation of mGlu4 Metabotropic Glutamate Receptors Reduces Nigrostriatal Degeneration in Mice Treated with 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine
Battaglia, G., Busceti, C. L., Molinaro, G., Biagioni, F., Traficante, A., Nicoletti, F., & Bruno, V. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.1595-06.2006 · Cited by 120
Allosteric agonists of 7TM receptors: expanding the pharmacological toolbox
Langmead, C. J., & Christopoulos, A. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.07.009 · Cited by 114
Self-citation
New Insights into the Function of M4 Muscarinic Acetylcholine Receptors Gained Using a Novel Allosteric Modulator and a DREADD (Designer Receptor Exclusively Activated by a Designer Drug)
Nawaratne, V., Leach, K., Suratman, N., Loiacono, R. E., Felder, C. C., Armbruster, B. N., Roth, B. L., Sexton, P. M., & Christopoulos, A. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.049353 · Cited by 112
Self-citation
Muscarinic Receptor Agonists and Antagonists in the Treatment of Alzheimers Disease
Clader, J. W., & Wang, Y. (2005) · Current Pharmaceutical Design · doi:10.2174/138161205774370762 · Cited by 112
Antiepileptic Drugs in Development: Prospects for the Near Future
Leppik, I. E. (1994) · Epilepsia · doi:10.1111/j.1528-1157.1994.tb05953.x · Cited by 108
Localization of Agonist- and Antagonist-Binding Domains of Human Corticotropin-Releasing Factor Receptors
Liaw, C. W., Grigoriadis, D. E., Lorang, M. T., Souza, E. B. D., & Maki, R. A. (1997) · Molecular Endocrinology · doi:10.1210/mend.11.13.0034 · Cited by 107
Thiochrome Enhances Acetylcholine Affinity at Muscarinic M4 Receptors: Receptor Subtype Selectivity via Cooperativity Rather than Affinity
Lazareno, S., Doležal, V., Popham, A., & Birdsall, N. J. M. (2004) · Molecular Pharmacology · doi:10.1124/mol.65.1.257 · Cited by 104
Targeting Group III Metabotropic Glutamate Receptors Produces Complex Behavioral Effects in Rodent Models of Parkinson's Disease
Lopez, S., Turle-Lorenzo, N., Acher, F., Leonibus, E. D., Mele, A., & Amalric, M. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.0299-07.2007 · Cited by 102
Allosteric Potentiators of Metabotropic Glutamate Receptor Subtype 5 Have Differential Effects on Different Signaling Pathways in Cortical Astrocytes
Zhang, Y., Rodriguez, A. L., & Conn, P. J. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.090308 · Cited by 102
Preclinical Pharmacology of mGlu2 / 3 Receptor Agonists: Novel Agents for Schizophrenia?
Schoepp, D. D., & Marek, G. J. (2002) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1568007024606177 · Cited by 100
Identification of Indole Derivatives Exclusively Interfering with a G Protein-Independent Signaling Pathway of the Prostaglandin D2 Receptor CRTH2
Mathiesen, J. M., Ulven, T., Martini, L., Gerlach, L. O., Heinemann, Á., & Kostenis, E. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.010520 · Cited by 100
Genetic Variations and Polymorphisms of G Protein-Coupled Receptors: Functional and Therapeutic Implications
Rana, B. K., Shiina, T., & Insel, P. A. (2001) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.593 · Cited by 100
NMDA-induced potentiation of mGluR5 is mediated by activation of protein phosphatase 2B/calcineurin
Alagarsamy, S., Saugstad, J. A., Warren, L., Mansuy, I. M., Gereau, R. W., & Conn, P. J. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.05.005 · Cited by 99
N-{4-Chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-hydroxybenzamide (CPPHA) Acts through a Novel Site as a Positive Allosteric Modulator of Group 1 Metabotropic Glutamate Receptors
Chen, Y., Goudet, C., Pin, J., & Conn, P. J. (2007) · Molecular Pharmacology · doi:10.1124/mol.107.040097 · Cited by 96
Progress in Mapping Human Epilepsy Genes
Delgado‐Escueta, A. V., Serratosa, J. M., Liu, A. Y., Weissbecker, K., Medina, M. T., Gee, M. N., Treiman, L. J., & Sparkes, R. S. (1994) · Epilepsia · doi:10.1111/j.1528-1157.1994.tb05926.x · Cited by 95
Group II mGlu Receptor Activation Suppresses Norepinephrine Release in the Ventral Hippocampus and Locomotor Responses to Acute Ketamine Challenge
Lorrain, D. S., Schaffhauser, H., Campbell, U. C., Baccei, C. S., Correa, L. D., Rowe, B. A., Rodriguez, D. E., Anderson, J. J., Varney, M. A., Pinkerton, A. B., et al. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300238 · Cited by 93
Group III Metabotropic Glutamate-Receptor-Mediated Modulation of Excitatory Transmission in Rodent Substantia Nigra Pars Compacta Dopamine Neurons
Valenti, O., Mannaioni, G., Seabrook, G. R., Conn, P. J., & Marino, M. J. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.080481 · Cited by 92
Site-Directed Mutagenesis Reveals Two Epitopes Involved in the Subtype Selectivity of the Allosteric Interactions of Gallamine at Muscarinic Acetylcholine Receptors
Gnagey, A. L., Seidenberg, M., & Ellis, J. (1999) · Molecular Pharmacology · doi:10.1124/mol.56.6.1245 · Cited by 91
Interaction of Novel Positive Allosteric Modulators of Metabotropic Glutamate Receptor 5 with the Negative Allosteric Antagonist Site Is Required for Potentiation of Receptor Responses
Chen, Y., Nong, Y., Goudet, C., Hemstapat, R., de Paulis, T., Pin, J., & Conn, P. J. (2007) · Molecular Pharmacology · doi:10.1124/mol.106.032425 · Cited by 89
Allosteric Site on Muscarinic Acetylcholine Receptors: Identification of Two Amino Acids in the Muscarinic M2 Receptor That Account Entirely for the M2/M5 Subtype Selectivities of Some Structurally Diverse Allosteric Ligands in N-Methylscopolamine-Occupied Receptors
Voigtländer, U., Jöhren, K., Mohr, M., Raasch, A., Tränkle, C., Buller, S., Ellis, J., Höltje, H., & Mohr, K. (2003) · Molecular Pharmacology · doi:10.1124/mol.64.1.21 · Cited by 88
Coordinate regulation of metabotropic glutamate receptors
Alagarsamy, S., Sorensen, S. D., & Conn, P. J. (2001) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(00)00219-1 · Cited by 84
Schizophrenia: Moving Beyond Monoamine Antagonists
Conn, P. J., Tamminga, C. A., Schoepp, D. D., & Lindsley, C. W. (2008) · Molecular Interventions · doi:10.1124/mi.8.2.7 · Cited by 84
Self-citation
Allosteric modulators of G-protein-coupled receptors
May, L. T. (2003) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(03)00107-3 · Cited by 84
Differential antagonism of the anticonflict effects of typical and atypical anxiolytics
Patel, J. B., Martin, C., & Malick, J. B. (1982) · European Journal of Pharmacology · doi:10.1016/0014-2999(82)90331-4 · Cited by 83
Group III mGluR regulation of synaptic transmission at the SC-CA1 synapse is developmentally regulated
Ayala, J. E., Niswender, C. M., Luo, Q., Banko, J. L., & Conn, P. J. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.12.009 · Cited by 80
Ethanol differentially affects ATP-gated P2X and P2X receptor subtypes expressed in oocytes
Davies, D. L., Kochegarov, A., Kuo, S. T., Kulkarni, A. A., WOODWARD, J., King, B. F., & Alkana, R. L. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.03.015 · Cited by 78
Calcium Sensing Receptor Activators: Calcimimetics
Harrington, P. E., & Fotsch, C. H. (2007) · Current Medicinal Chemistry · doi:10.2174/092986707782794096 · Cited by 75
Muscarinic agonists and antagonists in the treatment of Alzheimer's disease
Greenlee, W. J., CLADER, J. W., Asberom, T., McCombie, S. W., Ford, J., Guzik, H. S., Kozlowski, J. A., Li, S., Liu, C., Lowe, D., et al. (2001) · Il Farmaco · doi:10.1016/s0014-827x(01)01102-8 · Cited by 72
Challenges in the development of mGluR5 positive allosteric modulators: The discovery of CPPHA
Zhao, Z., Wisnoski, D. D., O’Brien, J. A., Lemaire, W., Williams, D. L., Jacobson, M. A., Wittman, M., Ha, S., Schaffhauser, H., Sur, C., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.11.081 · Cited by 71
Self-citation
A Novel Class of Positive Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 1 Interact with a Site Distinct from That of Negative Allosteric Modulators
Hemstapat, R., de Paulis, T., Chen, Y., Brady, A. E., Grover, V. K., Alagille, D., Tamagnan, G. D., & Conn, P. J. (2006) · Molecular Pharmacology · doi:10.1124/mol.105.021857 · Cited by 68
Treatment of Motor Fluctuations in Parkinsonʼs Disease with an Oral Sustained-Release Preparation of L-Dopa
Poewe, W., Lees, A. J., & Stern, G. M. (1986) · Clinical Neuropharmacology · doi:10.1097/00002826-198610000-00003 · Cited by 62
Allosteric Interactions with Muscarinic Acetylcholine Receptors: Complex Role of the Conserved Tryptophan M2422Trp in a Critical Cluster of Amino Acids for Baseline Affinity, Subtype Selectivity, and Cooperativity
Prilla, S., Schrobang, J., Ellis, J., Höltje, H., & Mohr, K. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.023481 · Cited by 59
Critical Amino Acid Residues of the Common Allosteric Site on the M2 Muscarinic Acetylcholine Receptor: More Similarities than Differences between the Structurally Divergent Agents Gallamine and Bis(ammonio)alkane-Type Hexamethylene-bis-[dimethyl-(3-phthalimidopropyl)ammonium]dibromide
Huang, X., Prilla, S., Mohr, K., & Ellis, J. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.014043 · Cited by 57
Allosteric Site on Muscarinic Acetylcholine Receptors: A Single Amino Acid in Transmembrane Region 7 Is Critical to the Subtype Selectivities of Caracurine V Derivatives and Alkane-Bisammonium Ligands
Buller, S., Zlotos, D. P., Mohr, K., & Ellis, J. (2002) · Molecular Pharmacology · doi:10.1124/mol.61.1.160 · Cited by 56
Point Mutations in the Transmembrane Region of GABAB2 Facilitate Activation by the Positive Modulator N,N′-Dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine (GS39783) in the Absence of the GABAB1 Subunit
Dupuis, D. S., Relkovic, D., Lhuillier, L., Mosbacher, J., & Kaupmann, K. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.028183 · Cited by 54
Recent Advances in Non-Competitive mGlu5 Receptor Antagonists and their Potential Therapeutic Applications
Slassi, A., Isaac, M. B., Edwards, L. G., Minidis, A. B. E., Wensbo, D., Mattsson, J. P., Nilsson, K. A., Raboisson, P., McLeod, D. A., Stormann, T. M., et al. (2005) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026054750236 · Cited by 54
Metabotropic glutamate receptor 2 modulates excitatory synaptic transmission in the rat globus pallidus
Poisik, O. V., Raju, D. V., Verreault, M., Rodriguez, A. L., Abeniyi, O. A., Conn, P. J., & Smith, Y. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.03.006 · Cited by 53
Application of a Kinetic Model to the Apparently Complex Behavior of Negative and Positive Allosteric Modulators of Muscarinic Acetylcholine Receptors
Avlani, V. A., May, L. T., Sexton, P. M., & Christopoulos, A. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.059840 · Cited by 53
Self-citation
Allosteric potentiators of the metabotropic glutamate receptor 2 (mGlu2). Part 3: Identification and biological activity of indanone containing mGlu2 receptor potentiators
Pinkerton, A. B., Cube, R. V., Hutchinson, J. H., James, J. K., Gardner, M. F., Rowe, B. A., Schaffhauser, H., Rodriguez, D. E., Campbell, U. C., Daggett, L. P., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.01.077 · Cited by 49
Changes of Cooperativity between N-Methylscopolamine and Allosteric Modulators Alcuronium and Gallamine Induced by Mutations of External Loops of Muscarinic M3 Receptors
Krejčı́, A., & Tucek, S. (2001) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12303-6 · Cited by 49
Benzazoles as allosteric potentiators of metabotropic glutamate receptor 2 (mGluR2): Efficacy in an animal model for schizophrenia
Govek, S. P., Bonnefous, C., Hutchinson, J. H., Kamenecka, T. M., McQuiston, J., Pracitto, R., Zhao, L., Gardner, M. F., James, J. K., Daggett, L. P., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.06.017 · Cited by 43
Allosteric Agonist Modulators
Kenakin, T. (2007) · Journal of Receptors and Signal Transduction · doi:10.1080/10799890701509000 · Cited by 43
Transposition of Three Amino Acids Transforms the Human Metabotropic Glutamate Receptor (mGluR)-3-Positive Allosteric Modulation Site to mGluR2, and Additional Characterization of the mGluR2-Positive Allosteric Modulation Site
Rowe, B. A., Schaffhauser, H., Morales, S., Lubbers, L. S., Bonnefous, C., Kamenecka, T. M., McQuiston, J., & Daggett, L. P. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.138271 · Cited by 40
Fish and fisheries of the Prespa lakes
Crivelli, A. J., Catsadorakis, G., Malakou, M., & Rosecchi, E. (1997) · Springer eBooks · doi:10.1007/978-94-011-5180-1_8 · Cited by 37
Asparagine, Valine, and Threonine in the Third Extracellular Loop of Muscarinic Receptor Have Essential Roles in the Positive Cooperativity of Strychnine-Like Allosteric Modulators
Jakubík, J., Krejčı́, A., & Doležal, V. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.080358 · Cited by 25
3-(2-Ethoxy-4-{4-[3-hydroxy-2-methyl-4-(3-methylbutanoyl)phenoxy]butoxy}phenyl)propanoic acid: a brain penetrant allosteric potentiator at the metabotropic glutamate receptor 2 (mGluR2)
Cube, R. V., Vernier, J., Hutchinson, J. H., Gardner, M. F., James, J. K., Rowe, B. A., Schaffhauser, H., Daggett, L. P., & Pinkerton, A. B. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.02.078 · Cited by 24
Recent Developments of the PET Imaging Agents for Metabotropic Glutamate Receptor Subtype 5
Yu, M. (2007) · Current Topics in Medicinal Chemistry · doi:10.2174/156802607782507394 · Cited by 24
Allosteric effects of four stereoisomers of a fused indole ring system with 3H-N-methylscopolamine and acetylcholine at M1–M4 muscarinic receptors
Lazareno, S., Birdsall, B., Fukazawa, T., Gharagozloo, P., Hashimoto, T., Kuwano, H., Popham, A., Sugimoto, M., & Birdsall, N. J. M. (1999) · Life Sciences · doi:10.1016/s0024-3205(98)00596-7 · Cited by 21
Metabotropic glutamate receptors mGluR4 and mGluR8 regulate transmission in the lateral olfactory tract–piriform cortex synapse
Jones, P. J., Xiang, Z., & Conn, P. J. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.06.043 · Cited by 18

Flagged first, then by citations

Research works printed but not linked: 2

Swanson, C. J., Bures, M., Johnson, M. P., Linden, A. M., Monn, J. A. & Schoepp, D. D. Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nature Rev. Drug Discov. 4, 131–144 (2005). · DOI · Paper page
Baez, M. et al. Molecular mapping of a subtype selective site for positive allosteric modulation of the mGlu2 receptor. Neuropharmacol. Abstr. 43, 274–275 (2002).

Sorted by citations

Molecular Dynamics Simulation for All
Hollingsworth, S. A., & Dror, R. O. (2018) · Neuron · doi:10.1016/j.neuron.2018.08.011 · Cited by 3,522
The structure and function of G-protein-coupled receptors
Rosenbaum, D. M., Rasmussen, S. G. F., & Kobilka, B. K. (2009) · Nature · doi:10.1038/nature08144 · Cited by 2,534
“This high conservation in the ligand-binding pocket is also observed in other subfamilies of GPCRs (such as dopamine, serotonin and histamine), and probably explains some of the difficulty in obtaining potent subtype-selective compounds in pharmaceutical discovery program”
Computational Methods in Drug Discovery
Sliwoski, G. R., Kothiwale, S., Meiler, J., & Lowe, E. W. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.007336 · Cited by 2,306
How were new medicines discovered?
Swinney, D. C., & Anthony, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3480 · Cited by 1,812
Role of Molecular Dynamics and Related Methods in Drug Discovery
Vivo, M. D., Masetti, M., Bottegoni, G., & Cavalli, A. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01684 · Cited by 1,358

See all 1,063

Authors: Jeffrey Conn, P., Christopoulos, A., & Lindsley, C. W.
Affiliations: Monash University (AU)
Vanderbilt University (US)
ORCID: Christopoulos, Arthur
Lindsley, Craig W.
Venue: Nature Reviews Drug Discovery
Publisher: Springer Science and Business Media LLC
Published: 2009-01
Volume: 8
Issue: 1
Pages: 41-54
ISSN: 1474-1776 (ISSN-L)
1474-1784
DOI: 10.1038/nrd2760
PMC: PMC2907734
OpenAlex: W2003736358
Cited by: 1,063
References: 139
Citations by year: 2026: 30 · 2025: 46 · 2024: 37 · 2023: 25 · 2022: 48 · 2021: 51 · 2020: 44 · 2019: 58 · 2018: 57 · 2017: 68 · 2016: 64 · 2015: 67 · 2014: 69 · 2013: 80 · 2012: 75
FWCI: 6.60
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature Reviews Drug Discovery (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Institute of Mental Health (R01MH073676, R01MH074953, R01MH062646)
National Institute on Drug Abuse (R01DA023926)
National Institute of Neurological Disorders and Stroke (R01NS031373)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords: G protein-coupled receptors, allosteric modulators, allosteric site, orthosteric ligands, mental illness, neurological disorders, CNS drug discovery, receptor selectivity, novel therapeutic agents
MeSH terms: Allosteric Regulation, Animals, Central Nervous System Diseases, Drug Evaluation, Preclinical, Humans, Ligands, Drug Design, Receptors, G-Protein-Coupled

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks